Ashurst

Ashurst is an international law firm founded in 1822 headquartered in London with over two centuries of history. It operates globally with more than 30 offices worldwide including key financial hubs like Hong Kong and New York. While not itself a life sciences or biotechnology company developing drugs or therapies directly—its core business lies in providing comprehensive legal advisory services to clients within the pharmaceutical industry as well as medical device manufacturers and medical research organizations. The firm's healthcare practice includes advising on intellectual property matters such as patent disputes/licensing/trademark issues relevant to pharma clients; regulatory compliance; competition disputes; corporate transactions including mergers/acquisitions/IPOs notably within Asia-Pacific markets like Hong Kong where they advised Luye Pharma Group's IPO—the largest pharmaceutical IPO globally at that time—and Boan Biotech’s spinoff from Luye Pharma Group. Key personnel include Matthias Wiedenfels who brings deep industry expertise from his prior CEO role at STADA Arzneimittel AG into advising pharma M&A deals at Ashurst. The firm's capabilities extend into helping biotech startups raise capital via public offerings alongside private equity funding advice while navigating complex regulatory environments across jurisdictions.